A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- Interventions
- Registration Number
- NCT06257875
- Lead Sponsor
- AbbVie
- Brief Summary
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult participants with moderate to severe UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed.
Lutikizumab is an investigational product being developed for the treatment of moderate to severe UC. Participants are placed in groups called treatment arms. Each group receives a different treatment. In the Induction Period, participants will be randomized into 1 of 3 arms receiving lutikizumab Dose 1, lutikizumab Dose 2, or adalimumab. In the Maintenance Period, participants who responded to lutikizumab will be randomized into 1 of 2 arms of lutikizumab maintenance and participants who responded to adalimumab will continue to receive adalimumab. All participants who did not achieve clinical response per modified Mayo Score at the end of the Induction period will receive open label lutikizumab. Around 200 adult participants with UC will be enrolled at approximately 280 sites worldwide.
During the 12 week Induction Period, participants will be randomized to receive intravenous (IV) and subcutaneous (SC) lutikizumab or SC adalimumab. At the 12 week mark, participants who are on lutikizumab who have responded to treatment will be re-randomized to receive SC lutikizumab at different intervals until Week 52. Participants who are on adalimumab who are responding to treatment will continue to receive adalimumab. Participants who do not respond to treatment will receive open-label SC lutikizumab. Participants who complete the Week 52 visit and in whom therapeutic benefit to study drug is confirmed by the investigator may roll over into an optional, blinded 52-week long-term extension (LTE).
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Participant has had a diagnosis of Ulcerative Colitis (UC) for at least 90 days prior to Baseline. Appropriate documentation of biopsy results consistent with the diagnosis of UC in the assessment of the investigator, must be available.
- Active UC with a Modified Mayo Score (mMS) of 5 to 9 points and Mayo Endoscopic Subscore (ESS) of 2 to 3 (confirmed by central review).
- Demonstrated inadequate response to, loss of response to, or intolerance to at least one of the following: oral aminosalicylates, corticosteroids, immunomodulators, and/or advanced therapies.
- Current diagnosis of Crohn's Disease (CD) or inflammatory bowel disease-unclassified.
- Extent of inflammatory disease limited to the rectum as assessed by screening endoscopy.
- Prior inadequate response, intolerance or loss of response to adalimumab (including biosimilars). Note: Participant may be enrolled if he/she discontinued adalimumab for reasons other than those listed above (e.g., loss of insurance) or he/she has been exposed to other advanced therapies, including anti-TNFs other than adalimumab.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Induction Group 1 Adalimumab Matching Placebo Participants will receive Dose 1 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction. Adalimumab placebo will be utilized to maintain the blind. Maintenance Group 1 Lutikizumab Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Adalimumab placebo will be utilized to maintain the blind. Induction Group 1 Lutikizumab Participants will receive Dose 1 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction. Adalimumab placebo will be utilized to maintain the blind. Induction Group 2 Adalimumab Matching Placebo Participants will receive Dose 2 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind. Induction Group 2 Lutikizumab Participants will receive Dose 2 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind. Induction Group 3 Lutikizumab Matching Placebo Participants will receive adalimumab per label throughout induction. Lutikizumab placebo will be utilized to maintain the blind. Induction Group 3 Adalimumab Participants will receive adalimumab per label throughout induction. Lutikizumab placebo will be utilized to maintain the blind. Maintenance Group 1 Adalimumab Matching Placebo Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Adalimumab placebo will be utilized to maintain the blind. Maintenance Non-Responders Lutikizumab Participants who do not respond to study drug at the end of induction period will receive open label SC lutikizumab in the maintenance period. Optional Long-Term Extension (LTE) Adalimumab Participants who complete the maintenance period, are willing/able to inject study drug at home, and in whom therapeutic benefit to study drug is confirmed by the investigator may participate in the optional 52-week blinded LTE. Maintenance Group 2 Lutikizumab Matching Placebo Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind. Maintenance Group 2 Adalimumab Matching Placebo Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind. Maintenance Group 2 Lutikizumab Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period. Lutikizumab placebo and adalimumab placebo will be utilized to maintain the blind. Maintenance Adalimumab Lutikizumab Matching Placebo Participants who respond to adalimumab induction group 3 will continue to receive adalimumab per label in the maintenance period. Lutikizumab placebo will be utilized to maintain the blind. Maintenance Adalimumab Adalimumab Participants who respond to adalimumab induction group 3 will continue to receive adalimumab per label in the maintenance period. Lutikizumab placebo will be utilized to maintain the blind. Optional Long-Term Extension (LTE) Lutikizumab Participants who complete the maintenance period, are willing/able to inject study drug at home, and in whom therapeutic benefit to study drug is confirmed by the investigator may participate in the optional 52-week blinded LTE.
- Primary Outcome Measures
Name Time Method Percentage of Participants who Achieve Endoscopic Improvement Week 12 Endoscopic Improvement is defined as Mayo Endoscopic Subscore (ESS) of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal appearance of mucosa; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Number of Participants with Adverse Events (AEs) Up to approximately Week 64 An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
- Secondary Outcome Measures
Name Time Method Percentage of Participants who Achieve Clinical Remission Per Modified Mayo Score (mMS) Week 12 Clinical remission on the mMS is defined as Endoscopy subscore = 0 or 1, AND Rectal bleeding subscore = 0, AND Stool frequency subscore \<= 1, AND not greater than baseline. The mMS is a composite score of UC disease activity based on the following 3 subscores: SFS, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal); RBS, scored from 0 (no blood seen) to 3 (blood alone passed); ESS, scored from 0 (normal appearance of mucosa) to 3 (severe disease \[spontaneous bleeding, ulceration\]). The overall mMS ranges from 0 to 9 with higher scores representing more severe disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.
Percentage of Participants who Achieve Clinical Response Per mMS Week 12 Clinical response per mMS is defined as decrease from baseline \>=2 points and \>=30%, PLUS a decrease in RBS \>= 1 or an absolute RBS \<=1. The mMS is a composite score of UC disease activity based on the following 3 subscores: SFS, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal); RBS, scored from 0 (no blood seen) to 3 (blood alone passed); ESS, scored from 0 (normal appearance of mucosa) to 3 (severe disease \[spontaneous bleeding, ulceration\]). The overall mMS ranges from 0 to 9 with higher scores representing more severe disease. The number of responders is calculated based on the total number of participants and estimated response rate, rounding to a nearest whole integer.
Percentage of Participants who Achieve Endoscopic Remission Week 12 Endoscopic remission is defined as Mayo Endoscopic Subscore (ESS) of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal appearance of mucosa; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Trial Locations
- Locations (188)
Tel Aviv Sourasky Medical Center /ID# 258528
🇮🇱Tel Aviv, Tel-Aviv, Israel
Gastro SB /ID# 258331
🇺🇸Chula Vista, California, United States
Southern California Res. Ctr. /ID# 258391
🇺🇸Coronado, California, United States
Newport Huntington Medical Group /ID# 258371
🇺🇸Huntington Beach, California, United States
Om Research LLC /ID# 261383
🇺🇸Lancaster, California, United States
UC Irvine Health /ID# 259824
🇺🇸Orange, California, United States
University of Colorado Hospital /ID# 258388
🇺🇸Aurora, Colorado, United States
Research Associates of South Florida, LLC /ID# 259813
🇺🇸Coral Gables, Florida, United States
University of Florida College of Medicine /ID# 260402
🇺🇸Gainesville, Florida, United States
Auzmer Research /ID# 260940
🇺🇸Lakeland, Florida, United States
Atlantic Medical Research /ID# 258507
🇺🇸Margate, Florida, United States
Homestead Associates in Research /ID# 260392
🇺🇸Miami, Florida, United States
University of Miami /ID# 258396
🇺🇸Miami, Florida, United States
JD Medical Group, LLC /ID# 261235
🇺🇸Miami, Florida, United States
Gastroenterology Group Naples /ID# 258346
🇺🇸Naples, Florida, United States
AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 260945
🇺🇸Orlando, Florida, United States
GCP Clinical Research, LLC /ID# 260401
🇺🇸Tampa, Florida, United States
Atlanta Ctr. for Gastro /ID# 259275
🇺🇸Decatur, Georgia, United States
Gastroenterology Associates of Central Georgia, LLC /ID# 258359
🇺🇸Macon, Georgia, United States
Gastroenterology Consultants, P.C /ID# 258352
🇺🇸Roswell, Georgia, United States
The University of Chicago DCAM /ID# 258491
🇺🇸Chicago, Illinois, United States
IU Health University Hospital /ID# 260398
🇺🇸Indianapolis, Indiana, United States
Univ Kansas Med Ctr /ID# 258489
🇺🇸Kansas City, Kansas, United States
Louisiana Research Center, LLC /ID# 258330
🇺🇸Shreveport, Louisiana, United States
Clin Res Inst of Michigan, LLC /ID# 258386
🇺🇸Chesterfield, Michigan, United States
Clin Res Inst of Michigan, LLC /ID# 259267
🇺🇸Chesterfield, Michigan, United States
Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 258493
🇺🇸Wyoming, Michigan, United States
Mayo Clinic - Rochester /ID# 258402
🇺🇸Rochester, Minnesota, United States
Univ New Mexico /ID# 258490
🇺🇸Albuquerque, New Mexico, United States
NY Scientific /ID# 260937
🇺🇸Brooklyn, New York, United States
NYU Langone Long Island Clinical Research Associates /ID# 258504
🇺🇸Lake Success, New York, United States
Weill Cornell Medicine/NYP /ID# 258953
🇺🇸New York, New York, United States
Columbia University Medical Center /ID# 258496
🇺🇸New York, New York, United States
Atrium Health /ID# 258506
🇺🇸Charlotte, North Carolina, United States
DJL Clinical Research, PLLC /ID# 259465
🇺🇸Charlotte, North Carolina, United States
Atrium Health Wake Forest Baptist Medical Center /ID# 260387
🇺🇸Winston-Salem, North Carolina, United States
Plains Clinical Research Center, LLC /ID# 258502
🇺🇸Fargo, North Dakota, United States
Digestive Disease Specialists /ID# 258499
🇺🇸Oklahoma City, Oklahoma, United States
Digestive Health Associates of Texas (DHAT) Research Institute - Garland /ID# 258358
🇺🇸Garland, Texas, United States
Baylor College of Medicine /ID# 258394
🇺🇸Houston, Texas, United States
BioStar Clinical Research Group - Houston - Katy Freeway /ID# 261164
🇺🇸Houston, Texas, United States
Clinical Associates in Research Therapeutics of America, LLC /ID# 258403
🇺🇸San Antonio, Texas, United States
Southern Star Research Institute, LLC /ID# 258347
🇺🇸San Antonio, Texas, United States
Tyler Research Institute, LLC /ID# 258383
🇺🇸Tyler, Texas, United States
Texas Digestive Disease Consultants - Webster /ID# 258718
🇺🇸Webster, Texas, United States
University Physicians and Surgeons Inc. /ID# 260399
🇺🇸Huntington, West Virginia, United States
Wisconsin Center for Advanced Research /ID# 258949
🇺🇸Milwaukee, Wisconsin, United States
Bankstown-Lidcombe Hospital /ID# 259089
🇦🇺Bankstown, New South Wales, Australia
Lyell McEwin Hospital /ID# 260580
🇦🇺Elizabeth Vale, South Australia, Australia
The Queen Elizabeth Hospital /ID# 259482
🇦🇺Woodville South, South Australia, Australia
St Vincent's Hospital Melbourne /ID# 259473
🇦🇺Fitzroy Melbourne, Victoria, Australia
Fiona Stanley Hospital /ID# 259480
🇦🇺Murdoch, Western Australia, Australia
Universitaetsklinikum St. Poelten /ID# 258256
🇦🇹Sankt Poelten, Niederoesterreich, Austria
Universite Libre de Bruxelles - Hopital Erasme /ID# 258214
🇧🇪Anderlecht, Bruxelles-Capitale, Belgium
CHU de Liège /ID# 258212
🇧🇪Liège, Liege, Belgium
UZ Gent /ID# 258210
🇧🇪Gent, Oost-Vlaanderen, Belgium
Vitaz /Id# 258222
🇧🇪Sint-Niklaas, Oost-Vlaanderen, Belgium
Universitair Ziekenhuis Leuven /ID# 258226
🇧🇪Leuven, Vlaams-Brabant, Belgium
AZ Maria Middelares /ID# 258219
🇧🇪Gent, Belgium
Hospital Tsaritsa Yoanna /ID# 258338
🇧🇬Sofiya, Sofia, Bulgaria
Medical Center - Doverie /ID# 261936
🇧🇬Sofiya, Sofia, Bulgaria
ACIBADEM City Clinic Diagnostic-Consultative Center /ID# 258339
🇧🇬Sofiya, Sofia, Bulgaria
Umbal Kaspela /ID# 258336
🇧🇬Plovdiv, Bulgaria
2nd Mhat /ID# 258337
🇧🇬Sofia, Bulgaria
UMHAT Sveti Ivan Rilski /ID# 261417
🇧🇬Sofia, Bulgaria
University Multiprofile Hospit /ID# 258878
🇧🇬Varna, Bulgaria
Gastroenterology and Internal Medicine Research Institution /ID# 258765
🇨🇦Edmonton, Alberta, Canada
Covenant Health /ID# 258799
🇨🇦Edmonton, Alberta, Canada
Toronto Digestive Disease Associates /ID# 260460
🇨🇦Vaughan, Ontario, Canada
Klinicki bolnicki centar Zagreb /ID# 258145
ðŸ‡ðŸ‡·Zagreb, Grad Zagreb, Croatia
Poliklinika Solmed /ID# 258147
ðŸ‡ðŸ‡·Zagreb, Grad Zagreb, Croatia
POLIKLINIKA BORZAN d.o.o. /ID# 258146
ðŸ‡ðŸ‡·Osijek, Osjecko-baranjska Zupanija, Croatia
Klinicki Bolnicki Centar (KBC) Split /ID# 258153
ðŸ‡ðŸ‡·Split, Splitsko-dalmatinska Zupanija, Croatia
Specijalna bolnica Medico Rijeka /ID# 258169
ðŸ‡ðŸ‡·Rijeka, Croatia
West Tallinn Central Hospital /ID# 262035
🇪🇪Tallinn, Harjumaa, Estonia
Medicum /ID# 268320
🇪🇪Tallinn, Harjumaa, Estonia
Parnu Hospital /ID# 261783
🇪🇪Parnu, Estonia
Tartu University Hospital /ID# 261782
🇪🇪Tartu, Estonia
Chu de Nice-Hopital L'Archet Ii /Id# 258041
🇫🇷Nice, Alpes-Maritimes, France
CHU Toulouse - Hopital Rangueil /ID# 258044
🇫🇷Toulouse, Haute-Garonne, France
Centre Hospitalier Universitaire de Saint Etienne - Hopital Nord /ID# 258040
🇫🇷St-Priest-en-Jarez, Loire, France
Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 258555
🇫🇷Creteil, Paris, France
CHU de Nantes, Hotel Dieu -HME /ID# 258042
🇫🇷Nantes, Pays-de-la-Loire, France
Universitaetsklinikum Ulm /ID# 258616
🇩🇪Ulm, Baden-Wuerttemberg, Germany
St. Marien- und St. Annastiftskrankenhaus /ID# 264691
🇩🇪Ludwigshafen am Rhein, Rheinland-Pfalz, Germany
Eugastro /ID# 260229
🇩🇪Leipzig, Sachsen, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 258614
🇩🇪Kiel, Schleswig-Holstein, Germany
Universitaetsklinikum Hamburg-Eppendorf /ID# 258617
🇩🇪Hamburg, Germany
Klinikum rechts der Isar /ID# 260228
🇩🇪Munich, Germany
General Hospital of Chest Diseases of Athens SOTIRIA /ID# 257831
🇬🇷Athens, Attiki, Greece
University General Hospital of Heraklion PA.G.N.I /ID# 257832
🇬🇷Heraklion, Kriti, Greece
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 257829
🇬🇷Athens, Greece
General Hospital of Thessaloniki Hippokrateio /ID# 260810
🇬🇷Thessaloniki, Greece
Clinfan /ID# 258094
ðŸ‡ðŸ‡ºSzekszárd, Tolna, Hungary
Clinexpert Kft /ID# 258449
ðŸ‡ðŸ‡ºBudapest, Hungary
Synexus Hungary Clinical Research Centre - Budapest /ID# 258915
ðŸ‡ðŸ‡ºBudapest, Hungary
Semmelweis Egyetem /ID# 258527
ðŸ‡ðŸ‡ºBudapest, Hungary
Szegedi Tudományegyetem /ID# 258095
ðŸ‡ðŸ‡ºSzeged, Hungary
St Vincent's University Hospital /ID# 261560
🇮🇪Elm Park, Dublin, Ireland
Beaumont Hospital /ID# 261561
🇮🇪Dublin, Ireland
Soroka University Medical Center /ID# 258530
🇮🇱Be'er Sheva, HaDarom, Israel
Yitzhak Shamir Medical Center /ID# 258533
🇮🇱Zerifin, HaMerkaz, Israel
The Chaim Sheba Medical Center /ID# 258532
🇮🇱Ramat Gan, Tel-Aviv, Israel
Hospital Universitario Virgen Macarena /ID# 258175
🇪🇸Sevilla, Spain
Shaare Zedek Medical Center /ID# 258529
🇮🇱Jerusalem, Yerushalayim, Israel
Rabin Medical Center /ID# 258531
🇮🇱Petah Tikva, Israel
Azienda Ospedaliero Universitaria di Cagliari - P.O. Duilio Casula /ID# 258455
🇮🇹Monserrato, Cagliari, Italy
Azienda Ospedaliera San Camillo Forlanini /ID# 258453
🇮🇹Rome, Roma, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 258452
🇮🇹Rome, Roma, Italy
IRCCS Ospedale Sacro Cuore Don Calabria /ID# 258456
🇮🇹Negrar, Verona, Italy
Gamagori City Hospital /ID# 260682
🇯🇵Gamagori-shi, Aichi, Japan
Aichi Medical University Hospital /ID# 258867
🇯🇵Nagakute, Aichi, Japan
Tsujinaka Hospital Kashiwanoha /ID# 258548
🇯🇵Kashiwa-shi, Chiba, Japan
Juntendo University Urayasu Hospital /ID# 259582
🇯🇵Urayasu-shi, Chiba, Japan
Kitakyushu Municipal Medical Center /ID# 259600
🇯🇵Kitakyushu, Fukuoka, Japan
Fukushima Medical University Hospital /ID# 259591
🇯🇵Fukushima-shi, Fukushima, Japan
Gifu University Hospital /ID# 259572
🇯🇵Gifu-shi, Gifu, Japan
Ogaki Municipal Hospital /ID# 259905
🇯🇵Ogaki-shi, Gifu, Japan
NHO Fukuyama Medical Center /ID# 258861
🇯🇵Fukuyama-shi, Hiroshima, Japan
Aoyama Clinic /ID# 259587
🇯🇵Kobe-shi, Hyogo, Japan
Hyogo Medical University Hospital /ID# 258827
🇯🇵Nishinomiya-shi, Hyogo, Japan
Sameshima Hospital /ID# 259589
🇯🇵Kagoshima-shi, Kagoshima, Japan
Kagoshima IBD Gastroenterology Clinic /ID# 259603
🇯🇵Kagoshima-shi, Kagoshima, Japan
Sai Gastroenterology and Proctology Clinic /ID# 260832
🇯🇵Fujidera-shi, Osaka, Japan
Kinshukai Infusion Clinic /ID# 259588
🇯🇵Osaka-shi, Osaka, Japan
Saga University Hospital /ID# 259625
🇯🇵Saga-shi, Saga, Japan
Tokitokai Tokito clinic /ID# 259036
🇯🇵Saitama-shi, Saitama, Japan
Hamamatsu University Hospital /ID# 259580
🇯🇵Hamamatsu-shi, Shizuoka, Japan
NHO Shizuoka Medical Center /ID# 259033
🇯🇵Sunto-gun, Shizuoka, Japan
Institute of Science Tokyo Hospital /ID# 259003
🇯🇵Bunkyo-ku, Tokyo, Japan
Tokai University Hachioji Hospital /ID# 258897
🇯🇵Hachioji-shi, Tokyo, Japan
Kyorin University Hospital /ID# 259843
🇯🇵Mitaka-shi, Tokyo, Japan
Center hospital of the National Center for Global Health and Medicine /ID# 259598
🇯🇵Shinjuku-ku, Tokyo, Japan
Toyama Prefectural Central Hospital /ID# 259499
🇯🇵Toyama-shi, Toyama, Japan
Inje University Haeundae Hospital /ID# 258822
🇰🇷Busan, Busan Gwang Yeogsi, Korea, Republic of
Dong-A University Medical Center /ID# 258423
🇰🇷Busan, Busan Gwang Yeogsi, Korea, Republic of
The Catholic University of Korea, Daejeon St. Mary's Hospital /ID# 258424
🇰🇷Daejeon, Daejeon Gwang Yeogsi, Korea, Republic of
Kangbuk Samsung Hospital /ID# 258416
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Samsung Medical Center /ID# 258420
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Yonsei University Health System Severance Hospital /ID# 258422
🇰🇷Seoul, Korea, Republic of
SIA Polana-D /ID# 262932
🇱🇻Daugavpils, Latvia
Liepaja Regional Hospital /ID# 261484
🇱🇻Liepaja, Latvia
Pauls Stradins Clinical University Hospital /ID# 261483
🇱🇻Riga, Latvia
Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 261486
🇱🇹Kaunas, Lithuania
Panevezys Republican Hospital /ID# 261780
🇱🇹Panevezys, Lithuania
Vilnius University Hospital Santaros Klinikos /ID# 261487
🇱🇹Vilnius, Lithuania
Waikato Hospital /ID# 258607
🇳🇿Hamilton, Waikato, New Zealand
Hutt Hospital /ID# 258608
🇳🇿Lower Hutt, Wellington, New Zealand
Dunedin Hospital /ID# 258584
🇳🇿Otago, New Zealand
Akershus Universitetssykehus /ID# 261586
🇳🇴Nordbyhagen, Akershus, Norway
Universitetssykehuset I Nord-Norge /ID# 261649
🇳🇴Tromsø, Troms, Norway
Centrum Medyczne Melita Medical /ID# 258379
🇵🇱Wrocław, Dolnoslaskie, Poland
Gastromed Sp. z o.o /ID# 258310
🇵🇱Torun, Kujawsko-pomorskie, Poland
Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska Sp. j. /ID# 258842
🇵🇱Ksawerow, Lodzkie, Poland
Medrise Sp. z o.o. /ID# 258561
🇵🇱Lublin, Lubelskie, Poland
Centrum Medyczne LukaMed Joanna Luka /ID# 258457
🇵🇱Chojnice, Pomorskie, Poland
H-T Centrum Medyczne Endoterapia /ID# 258540
🇵🇱Tychy, Slaskie, Poland
Twoja Przychodnia SCM /ID# 259280
🇵🇱Szczecin, Zachodniopomorskie, Poland
Clinical Research Investigator Group, LLC /ID# 260647
🇵🇷Bayamon, Puerto Rico
Caribbean Medical Research Center /ID# 268395
🇵🇷San Juan, Puerto Rico
School of Medicine University of Puerto Rico-Medical Science Campus /ID# 258508
🇵🇷San Juan, Puerto Rico
Clinical Hosp Center Zvezdara /ID# 257766
🇷🇸Belgrade, Beograd, Serbia
University Clinical Center Serbia /ID# 257764
🇷🇸Belgrade, Beograd, Serbia
Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 257768
🇷🇸Belgrade, Beograd, Serbia
Clin Hosp Ctr Bezanijska Kosa /ID# 257765
🇷🇸Belgrade, Beograd, Serbia
General Hospital Leskovac /ID# 257767
🇷🇸Leskovac, Jablanicki Okrug, Serbia
University Clinical Center Vojvodina /ID# 257763
🇷🇸Novi Sad, Serbia
General Hospital Celje /ID# 261482
🇸🇮Celje, Slovenia
Univ Medical Ctr Ljubljana /ID# 261474
🇸🇮Ljubljana, Slovenia
Splosna bolnisnica Murska Sobota /ID# 262486
🇸🇮Murska Sobota, Slovenia
Clinresco Centers /ID# 258431
🇿🇦Johannesburg, Gauteng, South Africa
Johese Clinical Research Midstream /ID# 260195
🇿🇦Pretoria, Gauteng, South Africa
Spoke Research Inc /ID# 258432
🇿🇦CAPE TOWN Milnerton, Western Cape, South Africa
Private Practice Dr MN Rajabally /ID# 260671
🇿🇦Cape Town, Western Cape, South Africa
Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 259114
🇪🇸Santiago de Compostela, A Coruna, Spain
Hospital Universitario de Navarra /ID# 258173
🇪🇸Pamplona, Navarra, Spain
Hospital Universitario La Paz /ID# 258172
🇪🇸Madrid, Spain
Inselspital, Universitaetsspital Bern /ID# 260106
🇨ðŸ‡Bern, Switzerland
Intesto /ID# 260114
🇨ðŸ‡Bern, Switzerland
National Taiwan University Hospital /ID# 258476
🇨🇳Taipei City, Taipei, Taiwan
National Taiwan University Hospital - Hsinchu branch /ID# 259422
🇨🇳Hsinchu City, Taiwan
China Medical University Hospital /ID# 258478
🇨🇳Taichung, Taiwan
Linkou Chang Gung Memorial Hospital /ID# 258724
🇨🇳Taoyuan City, Taiwan
Addenbrooke's Hospital /ID# 258744
🇬🇧Cambridge, Cambridgeshire, United Kingdom
Gartnavel General Hospital /ID# 258741
🇬🇧Glasgow, Glasgow City, United Kingdom
Guys and St Thomas NHS Foundation Trust /ID# 258730
🇬🇧London, Greater London, United Kingdom
Oxford University Hospitals NHS Foundation Trust /ID# 258745
🇬🇧Oxford, Oxfordshire, United Kingdom
Barts Health NHS Trust /ID# 258600
🇬🇧London, United Kingdom